Uveitis, Posterior
Ophthalmology
2
Pipeline Programs
3
Companies
3
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
1
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
3 companies ranked by most advanced pipeline stage
ANI PharmaceuticalsBAUDETTE, MN
1 program1
Fluocinolone Acetonide Intravitreal Implant 0.18 mgPhase 41 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
ANI PharmaceuticalsFluocinolone Acetonide Intravitreal Implant 0.18 mg
Alconanecortave acetate
Bausch + LombRetisert
Clinical Trials (3)
Total enrollment: 3 patients across 3 trials
Fluocinolone Acetonide Intravitreal Implant 0.18 mg in the Treatment of Chronic Non-Infectious Posterior Segment Uveitis
Start: Jun 2022Est. completion: Nov 2025
Phase 4Active Not Recruiting
Prophylactic Anecortave Acetate in Patients With a Retisert Implant
Start: Sep 2006Est. completion: Mar 2010
Phase 1Completed
Corneal Endothelial Cell Density in Eyes Treated With a Fluocinolone Acetonide Intravitreal Implant
Start: Jul 2017Est. completion: Mar 20193 patients
N/ACompleted
Related Jobs in Ophthalmology
Lead Data Manager
Genomics
Remote
5h ago
Cleanroom and Laboratory Technician
SAB BIO
6h ago
Product Specialist
Johnson & Johnson
Hangzhou, Zhejiang, China
21h ago
BM 喀什 PSR HY
Johnson & Johnson
Urumqi, Xinjiang, China
21h ago
Site Delivery Leader MLL
Johnson & Johnson
Gent, East Flanders, Belgium
21h ago
Clinical Operations Manager
Johnson & Johnson
Irvine, California, United States of America
21h ago
$117K - $201K/yr
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
3 companies competing in this space